Prospective Study of the Feedback From an Adherence Monitor on Asthma Control (INCA)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Inhaled medications are the mainstay of the therapeutic management of respiratory disorders. Considered by many to be 'simple' and 'easy' to use, clinicians are aware that inhalers are often improperly used. However, there is no tool that can detect and record errors in either the timing or the method dose administration
The investigators designed a device that makes an acoustic record each time an inhaler is used. Opening the device makes an acoustic file which is recorded, this file is "time-stamped" which means that the timing of drug administration is recorded. When the device is retrieved and acoustic analysis performed, the steps involved in using the inhaler can be determined. Hence, the subjects inhaler technique is assessed and errors in the inhaler use identified. Together this means that errors in inhaler technique and timing of use can be quantified.
In this study the investigators attached the device to a discus dry powder inhaler. In order to eliminate the behavioral component of adherence and identify the mechanical issues associated with effective inhaler use the investigators studied subjects who were already in Hospital and already prescribed a discus inhaler. The investigators hypothesized that the device would identify which errors in technique were the most common and that this would provide insight into how these errors might be eliminated.
| Condition | Intervention |
|---|---|
|
Asthma |
Behavioral: Feedback from a computer log of use of the inhaler |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Prospective Study of the Feedback From an Adherence Monitor on Asthma Control |
- Adherence rate [ Time Frame: at three months ] [ Designated as safety issue: No ]The rate of adherence at baseline and at the end of the study, which at the end of the 3 month of study will be assessed. The adherence will be the number of doses taken at the correct time. The correct time is twice a day, in a period not less than 6 hours between the last dose and the subsequent dose or at a time greater than 18 hours apart from the previous dose.
- Asthma quality of life score [ Time Frame: at 3 months ] [ Designated as safety issue: No ]The asthma quality of life score will be related to adherence, The baseline asthma quality of life score and the quality of life score at the end of three months will be subtracted and these will be correlated with the average rate of adherence over the three months.
| Estimated Enrollment: | 100 |
| Study Start Date: | February 2010 |
| Estimated Study Completion Date: | October 2012 |
| Estimated Primary Completion Date: | June 2012 (Final data collection date for primary outcome measure) |
-
Behavioral: Feedback from a computer log of use of the inhaler
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
This study will involve patients attending the respiratory clinic at Beaumont Hospital. Patients already prescribed salmeterol-fluticasone via a discus inhaler will be asked to participate.
Inclusion Criteria:
- Patients prescribed inhaled salmeterol/fluticasone
Exclusion Criteria:
- Smokers
- Allergy to salmeterol/fluticasone
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Professor Richard Costello, Professor of Medicine, Beaumont Hospital |
| ClinicalTrials.gov Identifier: | NCT01529697 History of Changes |
| Other Study ID Numbers: | BeaumontH |
| Study First Received: | February 7, 2012 |
| Last Updated: | February 8, 2012 |
| Health Authority: | Ireland: Irish Medicines Board |
Keywords provided by Beaumont Hospital:
|
Asthma Inhaler use |
Additional relevant MeSH terms:
|
Asthma Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases |
Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases |
ClinicalTrials.gov processed this record on May 23, 2013